The clinic sees the whole preventive picture
Physicians can interpret new information alongside established risk factors, physical assessment and existing diagnostic modalities.
Partner audience · Executive health clinics
Add a molecular layer to programs already built around earlier insight.
Executive health clinics bring together time, trust and multidisciplinary care. miRoncol adds microRNA intelligence: a current oncology application today and a longer-term platform for longitudinal, multi-disease research.
Current miCheckup availability, intended use and laboratory information should be confirmed independently from broader miRoncol research directions.
Partner strengthHigh-trust physician-led relationships
Program fitComprehensive annual or executive assessment
Current applicationmiCheckup Early Cancer Detection Test
Platform horizonLongitudinal and multi-disease intelligence
Why executive clinics are a natural channel
The program already has breadth. The opportunity is to add a new biological layer.
Executive clinics can connect a molecular result to medical history, imaging and follow-up in a way a standalone transaction cannot.
A result has somewhere to go
The program can coordinate review, follow-up imaging and referral rather than leaving the client with an isolated signal.
Annual relationships create longitudinal potential
A recurring clinical relationship can preserve earlier measurements and place future changes in personal context.
How integration works
Fit the test into the program,not the program around the test.
The best clinic workflow uses existing trust and operations while maintaining clear responsibility at every step.
Select the appropriate population
Use current eligibility and exclusion criteria for asymptomatic screening.
Coordinate sample collection
Connect the clinic visit to a defined accredited-laboratory pathway.
Review results clinically
Place the report within history, existing screening and physician judgment.
Complete the follow-up loop
Ensure a suspected signal leads to imaging and referral rather than uncertainty.
What this partnership creates
A differentiated client experience,and a credible setting for platform expansion.
The immediate value is a stronger preventive program. The longer-term value is an environment where new applications can be evaluated responsibly.
One coordinated prevention journey
The molecular result sits within a comprehensive visit rather than arriving as an unsupported standalone report.
Meaningful program differentiation
Clinics can add a novel scientific layer while retaining ownership of the care relationship and follow-up.
A structured longitudinal environment
With explicit research consent, clinics can help study baseline, change and intervention across well-characterized health histories.
Clinical and commercial discipline
Program differentiation must never outrun the evidence.
The clinic should distinguish current product capabilities from future research and communicate both positive and negative results responsibly.
Strong implementation
Defined clinical ownership
- Use current intended-use and eligibility criteria.
- Train teams on result limitations and standard screening.
- Keep physician review and follow-up explicit.
- Separate consented research from routine clinical service.
Avoid
Unsupported expansion
- Do not market research-stage disease branches as available tests.
- Do not present a negative result as an all-clear.
- Do not promise that every signal will identify a cancer.
- Do not replace established screening or diagnostic pathways.
Add the layer responsibly
Bring microRNA intelligence into a program built to act on information.
Start with the clinic population, current workflow and the clinical pathway that follows each result.